How GLP-1 drugs work (Ozempic, Wegovy, Mounjaro)

If you’re reading this, you’ve probably either started a weekly shot and want to know what it’s actually doing in there, or you’re weighing one and want the mechanism before the marketing.

GLP-1 drugs are lab-made copies of a gut hormone your body releases after you eat. That hormone, glucagon-like peptide-1, tells your pancreas to release insulin, slows how fast your stomach empties, and signals your brain that you’re full. The drugs keep that “you’re full” message switched on for about a week instead of a couple of minutes.

Your own GLP-1 taps your brain on the shoulder after a meal and lets go within minutes. The drug keeps its hand there all week.

For a lot of people the effect that stands out isn’t even on the scale. It’s that the low background hum of when do I get to eat again goes quiet. People call it “food noise,” and turning its volume down is most of what these drugs do. One thing worth saying up front: unlike most compounds in this reference, this corner is unusually well-proven. Semaglutide and tirzepatide are FDA-approved, with large human trials behind them, not research-chemical guesswork.

The hormone they’re copying

GLP-1, short for glucagon-like peptide-1, is one of your incretin hormones, the signals your gut fires off the moment food shows up. In a body without diabetes, GLP-1 spikes right after a meal, nudges out a little insulin to handle the incoming sugar, then fades. Here’s the catch for drugmakers: your own GLP-1 is gone in about two minutes, because an enzyme called DPP-4 chops it up almost the instant it appears. Perfect as a real-time signal, useless as a medicine. You can’t inject something that self-destructs before it does any work.

So a GLP-1 drug isn’t a foreign chemical bolted onto your biology. It’s a redesigned copy of a message your body already sends and already knows how to read. That’s a different starting point from most drugs, and a big part of why the category took off the way it did.

What a GLP-1 drug actually does once it’s in you

A GLP-1 drug works on three fronts at once, and the word for it, agonist, just means it flips the same switch the natural hormone does. First, the pancreas: it prompts insulin only when blood sugar is actually high, and dials back glucagon (the hormone that pushes sugar up), which is why it lowers glucose without the crash risk of some older diabetes drugs. Second, the stomach: it slows how fast food leaves, a bit like turning down the drain in a sink, so you feel full sooner and stay full longer. Third, and the one everyone’s really here for, the brain: GLP-1 receptors in your appetite centers read the signal as “full,” and that steady background “not hungry” quietly shrinks how much you eat.

Add it up. Less appetite, slower stomach, steadier blood sugar, and that’s the whole weight-and-glucose story. There’s no metabolism-melting magic and nothing is being burned off in the background. The drug mostly just turns down the drive to eat, and for people who’ve fought that drive on willpower alone for years, quiet is the entire point.

Why one shot lasts a week, not two minutes

GLP-1 drugs last a week because chemists rebuilt the peptide to survive. Two changes do the heavy lifting. First, they tweaked the molecule so DPP-4, the enzyme that shreds the natural hormone in minutes, can’t get a grip on it. Second, they bolted on a fatty-acid tail that works like velcro, latching the drug onto albumin, a big, abundant carrier protein drifting through your blood. Stuck to albumin, the drug rides along and gets released slowly instead of being filtered straight out by your kidneys.

That stretches its half-life, the time your body takes to clear half a dose, from a couple of minutes to roughly a week. That single trick is what turns a hormone you’d have to re-inject every few minutes into a once-a-week subcutaneous shot, a jab into the fat just under the skin. Dose by the week instead of by the meal, and the “full” signal never gets a chance to switch off.

One family, each reaching a little further

GLP-1 drugs come as a family of variations on one idea, each wired to pull more of the body’s own metabolic levers. Semaglutide, the compound in Ozempic and Wegovy, is a pure GLP-1 agonist, and it’s the one that turned the whole category into dinner-table conversation. Tirzepatide (Mounjaro and Zepbound) adds a second incretin receptor, GIP, so it’s working two gut signals instead of one, and in head-to-head trials it has generally driven more weight loss than semaglutide. Retatrutide is the investigational next step, adding a third target, the glucagon receptor, and it’s still in trials, not approved.

The pattern is hard to miss: stack more of your body’s own metabolic signals onto one molecule, and the effect grows. And here’s the honest good news. Semaglutide and tirzepatide are FDA-approved, with efficacy nailed down in large human trials. This is not “research use only” territory. Retatrutide is the exception, with promising early numbers but no finish line yet, so hold it a notch lower until the Phase 3 results land. The specific trial figures live on each compound’s page, tier-labeled, rather than getting hand-waved here. All of them sit in the wider GLP-1 and incretin family.

What GLP-1 drugs don’t do (the honest limits)

GLP-1 drugs come with real trade-offs, and going in clear-eyed matters. The most common side effects are gastrointestinal: nausea, and for some people vomiting, constipation, or diarrhea. That’s the direct flip side of deliberately slowing your gut, and it tends to be worst when you first start or step up the dose, which is exactly why doctors titrate the dose upward slowly instead of starting high.

Two honest open questions get far less airtime than the before-and-after photos. First, a meaningful share of the weight lost is muscle, not just fat, which is why protein and resistance training come up so often alongside these drugs. Second, appetite (and usually the weight) tends to return when people stop, because the signal stops too. That doesn’t make GLP-1 drugs a bad deal. It makes them a treatment you stay on rather than a one-time fix, and that’s worth knowing before you start. The full rundown lives on our risks and side effects page.

Where to go next

GLP-1 drugs are covered compound by compound in this reference, with the sources attached. For the specifics, start with semaglutide and tirzepatide; each opens with a plain-English answer, a key-facts block, and the actual trials. To watch how much human testing the whole class is racking up, the clinical-trials tracker counts it live. And if a word here tripped you, what a GLP-1 actually is has the one-paragraph version.